SCHEMBL208320

SCHEMBL208320

N#Cc1ccc(Nc2nc(-c3ccc(Cl)c(Cl)c3)cs2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VCP P55072 5/20 0.71
ALOX5 P09917 5/20 0.71
CFTR P13569 2/20 0.57
ABL1 P00519 4/20 0.55
EIF4E P06730 1/20 0.53
MAPT P10636 3/20 0.52
GAA P10253 2/20 0.52
KDM4E B2RXH2 2/20 0.52
POLB P06746 1/20 0.52
RECQL P46063 1/20 0.52
BLM P54132 1/20 0.52
AMY1A P0DUB6 2/20 0.51
ALOX15 P16050 2/20 0.51
TSHR P16473 2/20 0.51
TDP1 Q9NUW8 2/20 0.51
SPHK2 Q9NRA0 2/20 0.51
SPHK1 Q9NYA1 2/20 0.51
MEN1 O00255 1/20 0.51
DEGS1 O15121 1/20 0.51
MAP4K4 O95819 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6155931 0.93 VCP (0.67) VCPALOX5CFTRABL1MAPT
SCHEMBL205107 0.87 CFTR (0.65) VCPALOX5CFTRABL1EIF4E
SCHEMBL206229 0.86 VCP (0.76) VCPALOX5CFTRMAPTGAA
SCHEMBL205976 0.85 ALOX5 (0.80) VCPALOX5CFTRABL1MAPT
SCHEMBL10246014 0.83 ALOX5 (0.76) VCPALOX5CFTRABL1MAPT
SCHEMBL5325600 0.83 ALOX5 (1.00) VCPALOX5CFTRABL1MAPT
SCHEMBL12298368 0.82 ALOX5 (0.75) VCPALOX5CFTRMAPTKDM4E
SCHEMBL12298351 0.82 VCP (0.63) VCPALOX5CFTRMAPTGAA
SCHEMBL7109033 0.81 VCP (0.76) VCPALOX5CFTRMAPTGAA
SCHEMBL7111888 0.81 VCP (0.76) VCPALOX5CFTRMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE PIGS, CPT1A, SLC10A1 VCP 1270/4885ALOX5 3410/4885CFTR 111/4885
US-20070004711-A1 Thiazole compounds and methods of use PIGS, CPT1A, SLC10A1 VCP 1270/4885ALOX5 3410/4885CFTR 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.